As the healthcare debate wages on, tea parties are top of mind.
The report that claims UnitedHealth Group is telling employees to participate in “tea parties,” is simply not true, according to a UnitedHealth e-mail.
UnitedHealth spokesman John Parker said the company doesn’t share third-party event listings, but only information about town halls sponsored by members of Congress.
“It’s beneficial for United from a business perspective to educate others about town halls sponsored by members of Congress early in the healthcare debate process,” says Georgette Pascale, president, Pascale Communications LLC, a healthcare public relations firm in Pittsburgh, Pa.
“They are being proactive about information and getting to the forefront of the debate on the future structure of healthcare delivery in the United States,” she says. “In the current environment, I feel that sometimes big insurers are painted as bad guys so with this approach, they are not being left out of the conversation; they are simply educating/disseminating public information in a timely manner.”
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More